Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model

BACKGROUND: Multiple myeloma is an incurable B-cell malignancy with a natural history that involves alternating periods of remission and subsequent relapse. For relapsed and/or refractory multiple myeloma (RRMM), the typical patient currently receives more lines of therapy than has been feasible in...

Descripción completa

Detalles Bibliográficos
Autores principales: Bloudek, Lisa, Roy, Anuja, Kish, Jonathan K., Siegel, David S., Jagannath, Sundar, Globe, Denise, Orloski, Laurie, Kuriakose, Emil T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397815/
https://www.ncbi.nlm.nih.gov/pubmed/27459662
http://dx.doi.org/10.18553/jmcp.2016.22.8.991

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397815/
https://www.ncbi.nlm.nih.gov/pubmed/27459662
http://dx.doi.org/10.18553/jmcp.2016.22.8.991

Ejemplares similares